{
    "info": {
        "nct_id": "NCT05588453",
        "official_title": "A Phase I/II Study of Ex-Vivo Expanded Allogeneic Universal Donor (UD) TGFbi NK Cell Infusions in Combination with Temozolomide As a Lymphodepleting Agent in Patients with Melanoma Metastatic to the Brain",
        "inclusion_criteria": "* Histologically confirmed melanoma with stage IV disease\n* Radiologically confirmed brain metastasis (n >= 1) with at least one measurable central nervous system (CNS) lesion >= 10 mm on T1-weighted gadolinium enhanced magnetic resonance imaging (MRI) and unequivocal evidence of progression\n* No indication for stereotactic radiotherapy\n* At least 4 weeks from any anticancer treatment (cytotoxic chemotherapy, signal transduction inhibitors, immunotherapy or radiation)\n* Absolute neutrophil count (ANC) 1 x 10^9/L\n* Platelets > 100,000/L\n* Hemoglobin (Hgb) >= 10 g/dL\n* Creatinine =< 1.5 x upper limit of normal (ULN)\n* Albumin >= 2.5 g/dL\n* Serum bilirubin < 1.5 x ULN unless due to Gilbert's syndrome\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 5 x ULN if documented liver metastases or < 3 X ULN without liver metastasis\n* > 18 years old (y/o)\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Females of reproductive age must agree to the use of an effective contraceptive method while on treatment, beginning 2 weeks before the first dose of investigational product and for 28 days after the final dose of investigational product for women. Males able to father a child must practice adequate methods of contraception or completely abstain from intercourse from the first dose of investigational treatment until one week after the final dose of investigational treatment\n* Women of childbearing potential must have a negative serum pregnancy test within 14 days of enrollment and/or urine pregnancy test 48 hours prior to the administration of the first study treatment\n* Patient information and written informed consent form signed\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Planned or concurrent systemic treatment or radiation therapy\n* If requiring corticosteroids for cerebral edema, patients must be on a stable dose. Lowest dose of steroids needed to control CNS edema is recommended. Doses above 4 mg daily need to be cleared by principal investigator (PI) of the study\n* Known contra-indication to MRI\n* Patients with non-melanoma malignancies are excluded unless a complete remission has been achieved at least 3 years prior to study entry and no additional therapy is required or anticipated during the study period (exceptions include: non-melanoma skin cancers, in situ bladder cancer, in situ gastric cancer, in situ colon cancers, in situ cervical cancers/dysplasia, or in situ breast carcinoma)\n* Patients with other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study, such as:\n\n  * Active infection\n  * Current active hepatic or renal disease\n  * Pregnant women, women who are likely to become pregnant or are breastfeeding\n  * Patients with significantly altered mental status prohibiting the understanding of the study or with psychological, familial, sociological, or geographical conditions potentially hampering ability to consent, compliance with the study protocol, and follow-up schedule; those conditions should be discussed with the patient before remigration in the trial\n  * Patients who received any other investigational drugs within the 30 days prior to screening visit\n  * Leptomeningeal metastases diagnosed by MRI\n  * Inclusion in another therapeutic protocol within 30 days\n  * If steroids are necessary to control symptoms related to CNS metastases, patients should be on the lowest dose of steroids necessary to control symptoms",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Patient information and written informed consent form signed",
            "criterions": [
                {
                    "exact_snippets": "Patient information and written informed consent form signed",
                    "criterion": "written informed consent form",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patient information",
                    "criterion": "patient information",
                    "requirements": [
                        {
                            "requirement_type": "provided",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) 1 x 10^9/L",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) 1 x 10^9/L",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0-2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets > 100,000/L",
            "criterions": [
                {
                    "exact_snippets": "Platelets > 100,000/L",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 100000,
                                "unit": "/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* > 18 years old (y/o)",
            "criterions": [
                {
                    "exact_snippets": "> 18 years old (y/o)",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Albumin >= 2.5 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Albumin >= 2.5 g/dL",
                    "criterion": "albumin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2.5,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of childbearing potential must have a negative serum pregnancy test within 14 days of enrollment and/or urine pregnancy test 48 hours prior to the administration of the first study treatment",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing potential ... must have a negative serum pregnancy test within 14 days of enrollment",
                    "criterion": "serum pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days before enrollment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Women of childbearing potential ... urine pregnancy test 48 hours prior to the administration of the first study treatment",
                    "criterion": "urine pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 48,
                                "unit": "hours before first study treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Females of reproductive age must agree to the use of an effective contraceptive method while on treatment, beginning 2 weeks before the first dose of investigational product and for 28 days after the final dose of investigational product for women. Males able to father a child must practice adequate methods of contraception or completely abstain from intercourse from the first dose of investigational treatment until one week after the final dose of investigational treatment",
            "criterions": [
                {
                    "exact_snippets": "Females of reproductive age must agree to the use of an effective contraceptive method while on treatment, beginning 2 weeks before the first dose of investigational product and for 28 days after the final dose of investigational product for women.",
                    "criterion": "females of reproductive age",
                    "requirements": [
                        {
                            "requirement_type": "contraceptive use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraceptive method effectiveness",
                            "expected_value": "effective"
                        },
                        {
                            "requirement_type": "contraceptive use timing",
                            "expected_value": [
                                "2 weeks before first dose",
                                "while on treatment",
                                "28 days after final dose"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Males able to father a child must practice adequate methods of contraception or completely abstain from intercourse from the first dose of investigational treatment until one week after the final dose of investigational treatment",
                    "criterion": "males able to father a child",
                    "requirements": [
                        {
                            "requirement_type": "contraceptive use or abstinence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraceptive method adequacy",
                            "expected_value": "adequate"
                        },
                        {
                            "requirement_type": "contraceptive/abstinence timing",
                            "expected_value": [
                                "from first dose",
                                "until one week after final dose"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum bilirubin < 1.5 x ULN unless due to Gilbert's syndrome",
            "criterions": [
                {
                    "exact_snippets": "Serum bilirubin < 1.5 x ULN",
                    "criterion": "serum bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless due to Gilbert's syndrome",
                    "criterion": "Gilbert's syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Active infection",
            "criterions": [
                {
                    "exact_snippets": "Active infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Planned or concurrent systemic treatment or radiation therapy",
            "criterions": [
                {
                    "exact_snippets": "Planned or concurrent systemic treatment",
                    "criterion": "systemic treatment",
                    "requirements": [
                        {
                            "requirement_type": "planned_or_concurrent",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Planned or concurrent ... radiation therapy",
                    "criterion": "radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "planned_or_concurrent",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Leptomeningeal metastases diagnosed by MRI",
            "criterions": [
                {
                    "exact_snippets": "Leptomeningeal metastases diagnosed by MRI",
                    "criterion": "leptomeningeal metastases",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis_method",
                            "expected_value": "MRI"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Inclusion in another therapeutic protocol within 30 days",
            "criterions": [
                {
                    "exact_snippets": "Inclusion in another therapeutic protocol within 30 days",
                    "criterion": "inclusion in another therapeutic protocol",
                    "requirements": [
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study, such as:",
            "criterions": [
                {
                    "exact_snippets": "other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study",
                    "criterion": "other concurrent severe and/or uncontrolled medical disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "impact_on_study_participation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current active hepatic or renal disease",
            "criterions": [
                {
                    "exact_snippets": "Current active hepatic ... disease",
                    "criterion": "hepatic disease",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "current status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Current active ... renal disease",
                    "criterion": "renal disease",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "current status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who received any other investigational drugs within the 30 days prior to screening visit",
            "criterions": [
                {
                    "exact_snippets": "received any other investigational drugs within the 30 days prior to screening visit",
                    "criterion": "receipt of investigational drugs",
                    "requirements": [
                        {
                            "requirement_type": "time since last dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If steroids are necessary to control symptoms related to CNS metastases, patients should be on the lowest dose of steroids necessary to control symptoms",
            "criterions": [
                {
                    "exact_snippets": "steroids are necessary to control symptoms related to CNS metastases",
                    "criterion": "steroid use for CNS metastases symptom control",
                    "requirements": [
                        {
                            "requirement_type": "necessity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "patients should be on the lowest dose of steroids necessary to control symptoms",
                    "criterion": "steroid dose for CNS metastases symptom control",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": "lowest necessary to control symptoms"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known contra-indication to MRI",
            "criterions": [
                {
                    "exact_snippets": "Known contra-indication to MRI",
                    "criterion": "contra-indication to MRI",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "knowledge_status",
                            "expected_value": "known"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If requiring corticosteroids for cerebral edema, patients must be on a stable dose. Lowest dose of steroids needed to control CNS edema is recommended. Doses above 4 mg daily need to be cleared by principal investigator (PI) of the study",
            "criterions": [
                {
                    "exact_snippets": "If requiring corticosteroids for cerebral edema, patients must be on a stable dose.",
                    "criterion": "corticosteroid use for cerebral edema",
                    "requirements": [
                        {
                            "requirement_type": "dose stability",
                            "expected_value": "stable"
                        }
                    ]
                },
                {
                    "exact_snippets": "Lowest dose of steroids needed to control CNS edema is recommended.",
                    "criterion": "steroid dose for CNS edema",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": "lowest needed to control CNS edema"
                        }
                    ]
                },
                {
                    "exact_snippets": "Doses above 4 mg daily need to be cleared by principal investigator (PI) of the study",
                    "criterion": "steroid dose",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "mg daily"
                            }
                        },
                        {
                            "requirement_type": "PI clearance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant women, women who are likely to become pregnant or are breastfeeding",
            "criterions": [
                {
                    "exact_snippets": "Pregnant women",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "women who are likely to become pregnant",
                    "criterion": "pregnancy potential",
                    "requirements": [
                        {
                            "requirement_type": "likely to become pregnant",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "are breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "breastfeeding",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with non-melanoma malignancies are excluded unless a complete remission has been achieved at least 3 years prior to study entry and no additional therapy is required or anticipated during the study period (exceptions include: non-melanoma skin cancers, in situ bladder cancer, in situ gastric cancer, in situ colon cancers, in situ cervical cancers/dysplasia, or in situ breast carcinoma)",
            "criterions": [
                {
                    "exact_snippets": "Patients with non-melanoma malignancies are excluded unless a complete remission has been achieved at least 3 years prior to study entry",
                    "criterion": "history of non-melanoma malignancy",
                    "requirements": [
                        {
                            "requirement_type": "remission_status",
                            "expected_value": "complete remission"
                        },
                        {
                            "requirement_type": "remission_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "no additional therapy is required or anticipated during the study period",
                    "criterion": "requirement for additional therapy for prior non-melanoma malignancy",
                    "requirements": [
                        {
                            "requirement_type": "additional_therapy_required_or_anticipated",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "exceptions include: non-melanoma skin cancers, in situ bladder cancer, in situ gastric cancer, in situ colon cancers, in situ cervical cancers/dysplasia, or in situ breast carcinoma",
                    "criterion": "history of specific in situ or non-melanoma skin cancers",
                    "requirements": [
                        {
                            "requirement_type": "cancer_type",
                            "expected_value": [
                                "non-melanoma skin cancers",
                                "in situ bladder cancer",
                                "in situ gastric cancer",
                                "in situ colon cancers",
                                "in situ cervical cancers/dysplasia",
                                "in situ breast carcinoma"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with significantly altered mental status prohibiting the understanding of the study or with psychological, familial, sociological, or geographical conditions potentially hampering ability to consent, compliance with the study protocol, and follow-up schedule; those conditions should be discussed with the patient before remigration in the trial",
            "criterions": [
                {
                    "exact_snippets": "significantly altered mental status prohibiting the understanding of the study",
                    "criterion": "mental status",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "not significantly altered to the extent that it prohibits understanding of the study"
                        }
                    ]
                },
                {
                    "exact_snippets": "psychological, familial, sociological, or geographical conditions potentially hampering ability to consent, compliance with the study protocol, and follow-up schedule",
                    "criterion": "psychological, familial, sociological, or geographical conditions",
                    "requirements": [
                        {
                            "requirement_type": "impact on study participation",
                            "expected_value": "do not potentially hamper ability to consent, compliance with the study protocol, and follow-up schedule"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Histologically confirmed melanoma with stage IV disease",
            "criterions": []
        },
        {
            "line": "* At least 4 weeks from any anticancer treatment (cytotoxic chemotherapy, signal transduction inhibitors, immunotherapy or radiation)",
            "criterions": []
        },
        {
            "line": "* No indication for stereotactic radiotherapy",
            "criterions": []
        },
        {
            "line": "* Radiologically confirmed brain metastasis (n >= 1) with at least one measurable central nervous system (CNS) lesion >= 10 mm on T1-weighted gadolinium enhanced magnetic resonance imaging (MRI) and unequivocal evidence of progression",
            "criterions": []
        },
        {
            "line": "* Hemoglobin (Hgb) >= 10 g/dL",
            "criterions": []
        },
        {
            "line": "* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 5 x ULN if documented liver metastases or < 3 X ULN without liver metastasis",
            "criterions": []
        },
        {
            "line": "* Creatinine =< 1.5 x upper limit of normal (ULN)",
            "criterions": []
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}